Randomized phase II trial of a toll-like receptor 9 agonist oligodeoxynucleotide, PF-3512676, in combination with first-line taxane plus platinum chemotherapy for advanced-stage non-small-cell lung cancer.

MLA

Manegold C, et al. “Randomized Phase II Trial of a Toll-like Receptor 9 Agonist Oligodeoxynucleotide, PF-3512676, in Combination with First-Line Taxane plus Platinum Chemotherapy for Advanced-Stage Non-Small-Cell Lung Cancer.” Journal of Clinical Oncology, vol. 26, no. 24, Aug. 2008, pp. 3979–86. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edo&AN=105649335&authtype=sso&custid=ns315887.

APA

Manegold C, Gravenor D, Woytowitz D, Mezger J, Hirsh V, Albert G, Al-Adhami M, Readett D, Krieg AM, & Leichman CG. (2008). Randomized phase II trial of a toll-like receptor 9 agonist oligodeoxynucleotide, PF-3512676, in combination with first-line taxane plus platinum chemotherapy for advanced-stage non-small-cell lung cancer. Journal of Clinical Oncology, 26(24), 3979–3986.

Chicago

Manegold C, Gravenor D, Woytowitz D, Mezger J, Hirsh V, Albert G, Al-Adhami M, Readett D, Krieg AM, and Leichman CG. 2008. “Randomized Phase II Trial of a Toll-like Receptor 9 Agonist Oligodeoxynucleotide, PF-3512676, in Combination with First-Line Taxane plus Platinum Chemotherapy for Advanced-Stage Non-Small-Cell Lung Cancer.” Journal of Clinical Oncology 26 (24): 3979–86. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edo&AN=105649335&authtype=sso&custid=ns315887.